Moussa, M.J.; Khandelwal, J.; Wilson, N.R.; Naik, S.A.; Subbiah, V.; Campbell, M.T.; Msaouel, P.; Singh, P.; Alhalabi, O.
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr. Oncol. 2024, 31, 3342-3349.
https://doi.org/10.3390/curroncol31060254
AMA Style
Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O.
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Current Oncology. 2024; 31(6):3342-3349.
https://doi.org/10.3390/curroncol31060254
Chicago/Turabian Style
Moussa, Mohammad Jad, Jaanki Khandelwal, Nathaniel R. Wilson, Sagar A. Naik, Vivek Subbiah, Matthew T. Campbell, Pavlos Msaouel, Parminder Singh, and Omar Alhalabi.
2024. "Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy" Current Oncology 31, no. 6: 3342-3349.
https://doi.org/10.3390/curroncol31060254
APA Style
Moussa, M. J., Khandelwal, J., Wilson, N. R., Naik, S. A., Subbiah, V., Campbell, M. T., Msaouel, P., Singh, P., & Alhalabi, O.
(2024). Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Current Oncology, 31(6), 3342-3349.
https://doi.org/10.3390/curroncol31060254
